Market
SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
SOPHiA GENETICS and AstraZeneca announced a partnership to co-develop and launch two companion diagnostics for precision oncology therapies. The collaboration combines SOPHiA's diagnostic software platform with AstraZeneca's oncology drug portfolio, positioning both firms to expand their presence in the companion diagnostics market.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network